2013
Use of Remote Monitoring of Newly Implanted Cardioverter-Defibrillators
Akar JG, Bao H, Jones P, Wang Y, Chaudhry SI, Varosy P, Masoudi FA, Stein K, Saxon LA, Curtis JP. Use of Remote Monitoring of Newly Implanted Cardioverter-Defibrillators. Circulation 2013, 128: 2372-2383. PMID: 24043302, DOI: 10.1161/circulationaha.113.002481.Peer-Reviewed Original ResearchConceptsMedian odds ratioOdds ratioNational Cardiovascular Data Registry ICD RegistryRemote patient monitoringMultivariable logistic regressionHealth-related factorsImplanted cardioverter defibrillatorEligible patientsICD RegistryLack of enrollmentCurrent guidelinesCardioverter defibrillatorPatientsLogistic regressionLocal practice environmentMajor causeHealth insuranceSubsequent activationEnrollmentPractice environmentPatient monitoringPhysiciansActivationRPM systemSuccessful usePlasma Profiles of Matrix Metalloproteinases and Tissue Inhibitors of the Metalloproteinases Predict Recurrence of Atrial Fibrillation Following Cardioversion
Mukherjee R, Akar JG, Wharton JM, Adams DK, McClure CD, Stroud RE, Rice AD, DeSantis SM, Spinale FG, Gold MR. Plasma Profiles of Matrix Metalloproteinases and Tissue Inhibitors of the Metalloproteinases Predict Recurrence of Atrial Fibrillation Following Cardioversion. Journal Of Cardiovascular Translational Research 2013, 6: 528-535. PMID: 23722357, DOI: 10.1007/s12265-013-9471-2.Peer-Reviewed Original ResearchMeSH KeywordsAgedAtrial FibrillationBiomarkersChi-Square DistributionC-Reactive ProteinElectric CountershockFibrosisHeart AtriaHumansLogistic ModelsMatrix MetalloproteinasesMiddle AgedMultivariate AnalysisNatriuretic Peptide, BrainPeptide FragmentsPredictive Value of TestsRecurrenceRisk FactorsTime FactorsTissue Inhibitor of MetalloproteinasesTreatment OutcomeConceptsAF recurrenceMatrix metalloproteinasesMMP-9TIMP-4MMP-3N-terminus pro B type natriuretic peptideHigh-sensitivity C-reactive protein levelsPro-B-type natriuretic peptideTissue inhibitorC-reactive protein levelsB-type natriuretic peptideLevels of MMPsAtrial fibrillation recurrenceNovel biomarker panelAtrial volumeNatriuretic peptideAtrial fibrosisSinus rhythmPredicts RecurrenceBiomarker panelRecurrenceMultivariate analysisPostcardioversionProtein levelsPlasma samples
2008
Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy
Akar JG, Al-Chekakie MO, Fugate T, Moran L, Froloshki B, Varma N, Santucci P, Wilber DJ, Matsumura ME. Endothelial dysfunction in heart failure identifies responders to cardiac resynchronization therapy. Heart Rhythm 2008, 5: 1229-1235. PMID: 18774094, DOI: 10.1016/j.hrthm.2008.05.027.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapyFlow-mediated dilationBaseline flow-mediated dilationBaseline endothelial dysfunctionAdditive prognostic valueEndothelial dysfunctionCRT respondersWalk distanceResynchronization therapyPrognostic valueBrachial artery flow-mediated dilationArtery flow-mediated dilationBaseline functional capacityEndothelial function assessmentHeart failure mortalityHeart failure outcomesLikelihood of responseLogistic regression analysisQuality of lifeCurrent selection criteriaEndothelial functionHeart failureQRS durationCurrent guidelinesFunction assessment